The MURANO Study: Final Analysis and Retreatment/Crossover Substudy Results of VenR for Patients with Relapsed/Refractory CLL.
Stemcell science news,
Fixed-duration venetoclax-rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the Phase III…